According to this recent study, pre-existing hereditary genetics can impact progression and survival outcomes of a future malignancy and warrant prospective investigation of APOE genotype as a biomarker for melanoma outcome and therapeutic response.
To learn more about what kiwis think and New Zealand Health Research's (NZHR’s) responses to the challenges that face New Zealand’s health research sector, come along to one of NZHR's catered highly regarded, not to be missed, presentation and networking events. Find out what kiwis (and NZHR) think, and have your say.
The objective of this study was to quantify the consequences of a total ban on indoor tanning for short-term regulatory enforcement, for consumers, and the longer-term health economic effects. It concludes that three years after the nationwide ban, regulation enforcement activities have decreased, and consumers have adopted substitute tanning methods.
The objective of this recent study was to investigate the association between immune-related adverse events and recurrence-free survival in a clinical trial. It compares pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma, and concludes that the occurrence of immune-related adverse events was associated with longer recurrence-free survival in the pembrolizumab arm.
This review provides an overview on BRAF-V600 mutations in melanoma and will discuss their prognostic and clinical significance. Moreover, it will suggest a therapeutic algorithm that can drive therapeutic choice in a first-line setting for BRAF-V600 mutant melanoma patients.
Pregnancy‐associated melanoma is recognized in the published work; however, significant knowledge deficiencies exist. According to this recent case study, patients with a history of any documented melanoma risk factors, particularly dysplastic nevus syndrome, require close monitoring especially during pregnancy and early post‐partum.
In this webinar, expert panellists will discuss breakthrough melanoma trials, including those most recently unveiled at ASCO 2020, and what they mean for clinical practice in Australia.
The Melanoma Institute Australia has published a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes. It is available free for clinicians to use in their practices.
Findings of this recent study reveal some of the methylated differentially expressed genes and pathways that exist between melonoma and melanocytic nevi. Some critical genes were identified that may help to improve the diagnosis and treatment of melanoma.
There have been major advances in the understanding of melanoma since the last revision of the World Health Organization (WHO) classification in 2006. This recent analysis discusses the development of the 9 distinct types of melanoma and distinguishes them by their epidemiology, clinical and histologic morphology, and
genomic characteristics.